Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 901 - 925 of 14771 in total
Glutethimide is a hypnotic and sedative. Its use has been largely superseded by other drugs.
Approved
Illicit
Matched Description: … Glutethimide is a hypnotic and sedative. Its use has been largely superseded by other drugs. …
Matched Categories: … Hypnotics and Sedatives …
Lucinactant is a new synthetic peptide-containing surfactant for intratracheal use. It contains sinapultide, a novel, hydrophobic, 21-amino acid peptide (leucine and lysine repeating units, KL4 peptide) designed to mimic human surfactant protein-B (SB-P). More specifically, it mimics the C-terminal amphipathic helical domain of this protein. It also consists of phospholipids...
Approved
Investigational
Matched Description: … , POPG) and a fatty acid (palmitic acid). ... It contains sinapultide, a novel, hydrophobic, 21-amino acid peptide (leucine and lysine repeating units ... It also consists of phospholipids (dipalmitoylphosphatidylcholine, DPPC and palmitoyloleoyl phosphatidylglycerol …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Ceftobiprole is a fifth-generation semisynthetic cephalosporin antibacterial which is available commercially as the prodrug ceftobiprole medocaril. Ceftobiprole is a broad-spectrum agent with demonstrated activity against both Gram-positive and Gram-negative bacteria, including antibiotic-resistant strains of Staphylcoccus aureus (methicillin-resistant Staphylococcus aureus; MRSA). The EMA's Committee for Medicinal Products for Human Use (CHMP)...
Approved
Investigational
Matched Description: … infections and bacteremia in April 2024. ... Ceftobiprole is a broad-spectrum agent with demonstrated activity against both Gram-positive and Gram-negative ... was subsequently approved in the United States with additional indications for skin and skin structure …
A potent inhibitor of adenosine deaminase. The drug is effective in the treatment of many lymphoproliferative malignancies, particularly hairy-cell leukemia. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity.
Approved
Investigational
Matched Description: … It is also synergistic with some other antineoplastic agents and has immunosuppressive activity. …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Nucleic Acids, Nucleotides, and Nucleosides …
Secnidazole is a second-generation 5-nitroimidazole antimicrobial agent. It is structurally related to other 5-nitroimidazoles, including DB00916 and DB00911, but displays improved oral absorption and a longer terminal elimination half-life than other drugs in this class. Secnidazole is selective against many anaerobic Gram-positive and Gram-negative bacteria as well as protozoa. Once...
Approved
Matched Description: … to form a radical anion, thereby damaging and killing the target pathogen. ... It is structurally related to other 5-nitroimidazoles, including [DB00916] and [DB00911], but displays ... improved oral absorption and a longer terminal elimination half-life than other drugs in this class. …
Matched Categories: … azithromycin, fluconazole and secnidazole ... Antiparasitic Products, Insecticides and Repellents …
Pralsetinib, similar to the previously approved selpercatinib, is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A219751, L15986] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers, including non-small cell lung cancer. Although multikinase inhibitors, including cabozantinib, ponatinib,...
Approved
Investigational
Matched Description: … Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and ... [A202055] Pralsetinib (BLU-667) and [selpercatinib] (LOXO-292) represent the first generation of specific …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby preventing neurotrophin-Trk interaction and...
Approved
Investigational
Matched Description: … plays an important role in tumor cell growth and survival. ... receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and ... Trk activation, which results in both the induction of cellular apoptosis and the inhibition of cell …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Copanlisib is a selective pan-Class I phosphoinositide 3-kinase (PI3K) inhibitor with preferential activity against the alpha and delta isoforms. PI3K, a lipid kinase that activates downstream signalling pathways involved in cell survival and growth, that exists in different isoforms and is often overexpressed in hematological malignancies. Copanlisib was granted accelerated...
Approved
Investigational
Matched Description: … , that exists in different isoforms and is often overexpressed in hematological malignancies. ... pan-Class I phosphoinositide 3-kinase (PI3K) inhibitor with preferential activity against the alpha and ... PI3K, a lipid kinase that activates downstream signalling pathways involved in cell survival and growth …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times higher than that of the first generation...
Approved
Investigational
Matched Description: … [L6676] Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. ... [A179398] It is most commonly marketed under the name Inlyta® and is available in oral formulations. …
Matched Categories: … Benzamides and benzamide derivatives ... Antineoplastic and Immunomodulating Agents …
Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing...
Approved
Matched Description: … where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing and ... Approximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs ... [A7927] More specifically, deletions around the LREA motif in exon 19 and exon 21 L858R point mutations …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for...
Approved
Investigational
Matched Description: … Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6 ... ) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity ... granted approval of abemaciclib treatment under the market name Verzenio for the treatment of HR-positive and
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Crotamiton is a scabicidal and antipruritic agent available as a cream or lotion for topical use only. It is a colorless to slightly yellowish oil, having a faint amine-like odor. It is miscible with alcohol and with methanol.
Approved
Matched Description: … It is miscible with alcohol and with methanol. ... Crotamiton is a scabicidal and antipruritic agent available as a cream or lotion for topical use only …
Matched Categories: … Scabicides and Pediculicides …
Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC).[L8453,L8459] It was first approved for use in the United States in 2014. Within the spectrum of idiopathic pulmonary fibrosis treatment options, nintedanib is currently one...
Approved
Matched Description: … used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and ... agent for NSCLC, nintedanib, in combination with [Docetaxel], is reserved for patients who have tried and ... indicated for the condition (the other being [Pirfenidone]) and as such is used as a first-line treatment …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Tovorafenib is a selective type II RAF kinase inhibitor with anti-tumour activity. It was granted accelerated approval by the FDA, making it the first FDA approval of a systemic therapy for the treatment of pediatric low-grade glioma, with BRAF rearrangements. BRAF oncogenic mutations in cancers drive dysregulated cell growth, proliferation,...
Approved
Investigational
Matched Description: … growth and survival. ... [A263602] Tovorafenib inhibits BRAF and blocks dysregulated signalling pathways related to cancer cell ... [L50587] BRAF oncogenic mutations in cancers drive dysregulated cell growth, proliferation, and differentiation …
Elranatamab is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager. It is a humanized immunoglobulin 2-alanine kappa antibody derived from two monoclonal antibodies (mAbs), an anti-BCMA mAb and an anti-CD3 mAb, each of which contributes one heavy chain and one light chain to drug structure. The resulting 4-chain bispecific...
Approved
Investigational
Matched Description: … immunoglobulin 2-alanine kappa antibody derived from two monoclonal antibodies (mAbs), an anti-BCMA mAb and ... an anti-CD3 mAb,[A261060] each of which contributes one heavy chain and one light chain to drug structure …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab...
Approved
Matched Description: … (white blood cells) and is important for the function of T cells, B cell, mast cells and neutrophils ... signaling pathways, including B-cell receptor (BCR) signaling and C-X-C chemokine receptors type 5 and ... type 4 signalling, which are involved in trafficking and homing of B-cells to the lymph nodes and bone …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Gadobenic acid, usually available in the salt form gadobenate dimeglumine, is a linear MRI gadolinium-based contrast agent (GBCA) used primarily for MR imaging of the liver. It differs from other GBCAs due to the benzene ring that confers weak protein binding, thus leading to an increased R1 and R2 relaxivity....
Approved
Investigational
Matched Description: … [A263166] As gadobenate dimeglumine is specifically taken up by hepatocytes and excreted through the ... other GBCAs due to the benzene ring that confers weak protein binding, thus leading to an increased R1 and
Hexocyclium is a muscarinic acetylcholine receptor antagonist which was presumably used in the treatment of gastric ulcer or diarrhea. It was once available under the tradename Tral marketed by Abbvie Inc. but has been discontinued. Proton pump inhibitors like DB00338 and opiate anti-diarrheal agents like DB00836 have largely replaced the...
Approved
Matched Description: … the use of anti-muscarinics in the treatment of gastric ulcers and diarrhea due to their more favorable ... Proton pump inhibitors like [DB00338] and opiate anti-diarrheal agents like [DB00836] have largely replaced …
Matched Categories: … Alimentary Tract and Metabolism …
Rabies virus inactivated antigen, A is an inactivated virus vacine for the intramuscular injection. It is an active immunization against rabies that can be administered pre- or post-exposure to the rabies virus.
Approved
Investigational
Matched Categories: … Immune Sera and Immunoglobulins …
Iptacopan is a small-molecule factor B inhibitor previously investigated as a potential treatment for the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) by inhibiting the complement factor B. Factor B is a positive regulator of the alternative complement pathway, where it activates C3 convertase and subsequently C5 convertase. This is...
Approved
Investigational
Matched Description: … the glycosyl phosphatidylinositol–anchored proteins that normally anchor 2 membrane proteins, CD55 and ... Factor B is a positive regulator of the alternative complement pathway, where it activates C3 convertase and ... , where 82.3% and 77.5% of patients experienced a sustained hemoglobin improvement without transfusions …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Sulfaphenazole is a sulfonamide antibacterial.
Approved
Matched Categories: … Sulfonamides and trimethoprim ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …
Ethambutol is a bacteriostatic agent indicated alongside medications such as isoniazid, rifampin, and pyrazinamide in the treatment of pulmonary tuberculosis. Ethambutol was first described in the literature in 1961. It was developed out of a need for therapies active against isoniazid resistant strains of Mycobacterium tuberculosis. Ethambutol was granted FDA...
Approved
Matched Description: … Ethambutol is a bacteriostatic agent indicated alongside medications such as [isoniazid], [rifampin], and
Matched Categories: … ethambutol and isoniazid ... rifampicin, ethambutol and isoniazid ... rifampicin, pyrazinamide, ethambutol and isoniazid …
Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States.
Approved
Investigational
Withdrawn
Matched Description: … QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and
Synthetic guanethidine derivative that locates phaeochromocytomas and neuroblastomas. The radioisotope used can either be iodine-123 for imaging or iodine-131 for destruction of tissues that metabolize noradrenaline. Iodine 123 is a cyclotron-produced radionuclide that decays to Te 123 by electron capture. Images are produced by a I123 MIBG scintigraphy. FDA approved...
Approved
Investigational
Matched Description: … Synthetic guanethidine derivative that locates phaeochromocytomas and neuroblastomas. …
Matched Categories: … Indicators and Reagents …
Xanthan gum is a polysaccharide gum derived from* Xanthomonas campestris* by a pure-culture fermentation process and purified by recovery with isopropyl alcohol. The major constituents include D-glucose, D-mannose, and D-glucuronic acid. Xanthan gum is a direct food additive permitted for direct addition to food for human consumption by the FDA....
Approved
Matched Description: … It is used as a thickening agent and stabilizer in emulsions. ... The major constituents include D-glucose, D-mannose, and D-glucuronic acid. ... is a polysaccharide gum derived from* Xanthomonas campestris* by a pure-culture fermentation process and
Matched Categories: … Diet, Food, and Nutrition …
Displaying drugs 901 - 925 of 14771 in total